Following a recent announcement in March 2021, BNP Paribas has received all the necessary approvals and completed the acquisition of 100% of Exane.
Following a recent announcement in March 2021, BNP Paribas has received all the necessary approvals and completed the acquisition of 100% of Exane, thus raising its stake from the 50% previously held during a successful 17-year partnership.
This milestone represents a new chapter for BNP Paribas and Exane, thanks to the strong collaboration from the teams of both firms. The acquisition enables the bank to fully leverage Exane’s expertise in cash equities (execution and research) and derivatives, offering to institutional investors and corporates globally a full suite of services and solutions on equities.
The acquisition of Exane, together with the transfer of Deutsche Bank’s Global Prime Finance and Electronic Equities business to BNP Paribas, positions BNP Paribas as a European leader in Global Equities. It also supports CIB’s ambition in Equity Capital Markets and M&A.
Yann Gérardin, Head of Corporate & Institutional Banking, and Chief Operating Officer, BNP Paribas
Exane plays a key role in BNP Paribas Global Markets’ fully-fledged equity ambition as we bring in cash equities, while continuing to strengthen our flow and derivatives offerings, and expanding the prime services business through the new integrated platform from Deutsche Bank. We look forward to welcome our Exane colleagues to the bank.
Olivier Osty, Head of Global Markets, BNP Paribas
BNP Paribas acquired Exane in 2021, following a successful and exclusive 17-year partnership. As a leading European equities business, BNP Paribas Exane offers you an award winning research product renowned for its depth and quality, provided to experienced, top-ranked Sales & Specialist Sales teams as well as a dedicated corporate access service.
You may also like
Related solutions
